September 23, 2016

First clinical trial to study GLP-1 receptor agonist and SGLT-2 inhibitor combination shows positive results

Experts have speculated that combination GLP-1 receptor agonist and SGLT-2 inhibitor therapy may have synergistic, beneficial effects in the treatment of type 2 diabetes. Now there are data to support this, as results of DURATION-8, the first clinical trial to study the combination as an addition to standard-of-care therapy, were recently announced at the European Association for the Study of Diabetes (EASD) 2016 Annual Meeting and published in the Lancet Diabetes and Endocrinology. Read more

Share onShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn